Paranasal sinus squamous cell carcinoma

Summary

Paranasal sinus squamous cell carcinoma (MONDO:0044705) is a cancer and 10 clinical trials. Top therapeutic interventions include cabozantinib, capecitabine, and lovastatin. A subtype of paranasal sinus carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 1 000 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 10

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.35	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	paranasal sinus squamous cell carcinoma
Mondo ID	MONDO:0044705
Orphanet	500464
DOID	DOID:2442
NCIT	C8193
UMLS	C0280334
MedGen	79105
GARD	0017927
Anatomy (UBERON)	UBERON:0001825
Is cancer (heuristic)	yes

Also known as: epidermoid carcinoma of paranasal sinus · epidermoid carcinoma of the paranasal sinus · paranasal sinus epidermoid carcinoma · paranasal sinus squamous cell carcinoma · squamous cell carcinoma of paranasal sinus · squamous cell carcinoma of the nasal cavity and sinuses · squamous cell carcinoma of the paranasal sinus

Disease family

This is a subtype of paranasal sinus carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone carcinoma › paranasal sinus carcinoma › paranasal sinus squamous cell carcinoma

Related subtypes (7): maxillary sinus carcinoma, frontal sinus cancer, paranasal sinus sarcoma, ethmoid sinus cancer, sphenoidal sinus cancer, paranasal sinus adenoid cystic carcinoma, paranasal sinus mucoepidermoid carcinoma

Subtypes (4): sphenoid sinus squamous cell carcinoma, frontal sinus squamous cell carcinoma, ethmoid sinus squamous cell carcinoma, maxillary sinus squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE2	3
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03468218	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
NCT06636734	PHASE2	RECRUITING	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT01267240	PHASE2	TERMINATED	Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT03370276	PHASE1/PHASE2	COMPLETED	Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT04576091	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
NCT05172245	PHASE1	RECRUITING	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT07156227	PHASE1	NOT_YET_RECRUITING	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
NCT03381183	PHASE1	COMPLETED	IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
NCT06662058	Not specified	RECRUITING	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
NCT03032250	Not specified	COMPLETED	Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	1
CAPECITABINE	4	1
LOVASTATIN	4	1
VORINOSTAT	4	1
IPATASERTIB	3	1
CAMONSERTIB	2	1
IRX-2	2	1
ELIMUSERTIB	1	1
CHEMBL4215501	0	1
CHEMBL4849721	0	1
EXELIXIS	0	1